LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.21 5.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.1400000000000001

Max

1.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.5M -20M
EPS	-0.32
Angestellte	49
EBITDA	6.8M -22M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+132.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.2M 73M
Vorheriger Eröffnungskurs	-4.01
Vorheriger Schlusskurs	1.21

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

20. Mai 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. Mai 2026, 22:52 UTC

Wichtige Markttreiber

Osisko Shares Fall on Planned Convertible Notes Offering

20. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. Mai 2026, 23:44 UTC

Ergebnisse

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. Mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. Mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. Mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. Mai 2026, 23:14 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. Mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. Mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. Mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. Mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. Mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. Mai 2026, 22:10 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. Mai 2026, 22:00 UTC

Ergebnisse

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. Mai 2026, 21:38 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. Mai 2026, 21:27 UTC

Ergebnisse

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. Mai 2026, 21:20 UTC

Ergebnisse

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. Mai 2026, 21:19 UTC

Ergebnisse

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. Mai 2026, 21:18 UTC

Ergebnisse

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. Mai 2026, 21:17 UTC

Ergebnisse

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. Mai 2026, 21:16 UTC

Ergebnisse

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

132.17% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 132.17%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.